Chronic myelogenous leukemia: molecular monitoring in clinical practice

Abstract

Use of tyrosine kinase inhibitor imatinib has led to significant progress in chronic myeloid leukemia (CML) treatment. To date, genetic monitoring is a mandatory attribute of therapy with tyrosine kinase inhibitors. The purpose of this study was to access the imatinib therapy efficacy in CML patients using complete molecular genetic monitoring by standard cytogenetics, realtime polymerase chain reaction and mutational analysis. Correlation between cytogenetic and molecular response was shown. Heterogeneity of molecular response in each patient group was revealed by expression of BCR-ABL. Kinase domain mutations were detected in 32 % of CML patients resistant to imatinib.

Keywords

• chronic myeloid leukemia
• molecular genetic monitoring
• Ph-positive cells mutations